Literature DB >> 12818578

Polymorphic SERCA2a variants do not account for inter-individual differences in phospholamban-SERCA2a interactions in human heart failure.

Albrecht G Schmidt1, Kobra Haghighi, Beate Frank, Luke Pater, Gerald W Dorn, Richard A Walsh, Evangelia G Kranias.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818578     DOI: 10.1016/s0022-2828(03)00111-1

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


× No keyword cloud information.
  5 in total

1.  Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure.

Authors:  B M Mayosi; A Kardos; C H Davies; F Gumedze; A Hovnanian; S Burge; H Watkins
Journal:  Heart       Date:  2005-04-21       Impact factor: 5.994

Review 2.  Endoplasmic-reticulum calcium depletion and disease.

Authors:  Djalila Mekahli; Geert Bultynck; Jan B Parys; Humbert De Smedt; Ludwig Missiaen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 3.  The role of SERCA2a/PLN complex, Ca(2+) homeostasis, and anti-apoptotic proteins in determining cell fate.

Authors:  Elizabeth Vafiadaki; Vasiliki Papalouka; Demetrios A Arvanitis; Evangelia G Kranias; Despina Sanoudou
Journal:  Pflugers Arch       Date:  2008-04-16       Impact factor: 3.657

4.  Identification of biochemical adaptations in hyper- or hypocontractile hearts from phospholamban mutant mice by expression proteomics.

Authors:  Yan Pan; Thomas Kislinger; Anthony O Gramolini; Elena Zvaritch; Evangelia G Kranias; David H MacLennan; Andrew Emili
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

5.  Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia.

Authors:  Annukka Marjamaa; Päivi Laitinen-Forsblom; Annukka M Lahtinen; Matti Viitasalo; Lauri Toivonen; Kimmo Kontula; Heikki Swan
Journal:  BMC Med Genet       Date:  2009-02-12       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.